Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kroidl, I; Winter, S; Rubio-Acero, R; Bakuli, A; Geldmacher, C; Eser, TM; Déak, F; Horn, S; Zielke, A; Ahmed, MIM; Diepers, P; Guggenbühl, J; Frese, J; Bruger, J; Puchinger, K; Reich, J; Falk, P; Markgraf, A; Fensterseifer, H; Paunovic, I; Thomschke, A; Pritsch, M; Riess, F; Saathoff, E; Hoelscher, M; Olbrich, L; Castelletti, N; Wieser, A, , KoCo19/ORCHESTRA, Study, Group.
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.
Virol J. 2023; 20(1): 200
Doi: 10.1186/s12985-023-02167-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Klugherz Isabel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). METHODS: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. RESULTS: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43-51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. CONCLUSION: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- COVID-19 - diagnosis
- SARS-CoV-2 - genetics
- Antibodies, Viral - administration & dosage
- Biological Assay - administration & dosage
- Immunoglobulin G - administration & dosage
- Find related publications in this database (Keywords)
- Antibody
- COVID-19
- Nucleocapsid
- RBD
- SARS-CoV-2
- Serology
- Spike
- Binding antibody units